Victor W. Nitti

Victor W. Nitti

Victor W. Nitti

Victor W. Nitti, MD, is Professor of Urology and Obstetrics and Gynecology and the Vice Chairman of the Department of Urology at New York University Langone Medical Center. He is also the head of Female Pelvic Medicine and Reconstructive Surgery and is the fellowship director for that ACGME accredited program. He is a graduate of the University of Medicine and Dentistry of New Jersey and did his urology residency at SUNY Downstate in Brooklyn, NY. He then completed a fellowship in female urology, neurourology and reconstructive urology at UCLA.

Dr. Nitti served on the faculty at SUNY Brooklyn before joining the faculty of NYU in 1995. He is an authority in urodynamic techniques, medical and surgical therapies for urinary incontinence, pelvic organ prolapse, female pelvic reconstructive surgery and voiding dysfunction. He has authored over 140 peer-reviewed articles as well and over 60 book chapters on these subjects. He is the editor of two text books:Practical Urodynamics, published by W. B. Saunders and Vaginal Surgery for the Urologist published by Elsevier. He has presented his research at national and international meetings and has been invited as a visiting professor and participated in postgraduate courses throughout the world. In 2015 he was the recipient of the AUA’s Victor Politano Award for expertise and contributions in urodynamics, medical and surgical therapies for urinary incontinence, female pelvic reconstruction and voiding dysfunction.

Dr. Nitti is a Fellow of the American College of Surgeons (ACS) and the American Board of Urology (ABU) and a member of the American Urological Association (AUA), the Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), The American Urogynecologic Society (AUGS), the International Continence Society (ICS) and the 1

st, 2nd, 3rd, 4th and 5th International Consultation on Incontinence (ICI). He currently holds the position of Chair, American Urological Association Office of Education and is the secretary of the New York Section of the AUA. He served as President of SUFU from 2010-2012. He currently serves on the FPMRS Division of the American Board of Obstetrics and Gynecology Dr. Nitti is on the editorial boards of

Neurourology and Urodynamics, the Journal of Female Pelvic Medicine and Reconstructive Surgery, and the International Urogynecology Journal


Neal Shore

Neal D. Shore


Neal D. Shore, MD, FACS

Director, CPI, Carolina Urologic Research Center

Atlantic Urology Clinics

Myrtle Beach, South Carolina

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Society of Urologic Oncology Clinical Trials Consortium, and the Large Urology Group Practice Association, currently President-elect. He has served on the AUA Male Health Committee; he is currently a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Urology Times, Current Urology Reports, Chemotherapy Advisor, OncLive, PlosOne and Urology Practice. He has numerous peer reviewed publications and book chapters; he performs peer review for numerous scientific journals.

A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6 month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

SC Jeff Chueh

S Jeff Chueh

SC_Jeff_chuehBrief Biography of S Jeff Chueh, MD, PhD.

Dr. S Jeff Chueh is currently a Staff Urologist at Center for Robotic and Minimally Invasive Surgery, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation; Section Head of Urology Practice at Cleveland Clinic Avon Hospital, Avon, OH and also a Clinical Professor of Surgery (Urology), Cleveland Clinic Lerner College of Medicine. He was the Medical Director and Primary Kidney Transplant Surgeon at West Virginia CAMC Kidney Transplant Program—affiliated with Cleveland Clinic; and a Professor & Attending Staff at Department of Urology, College of Medicine, National Taiwan University and NTU Hospital.

Dr. Chueh is well published academically. He has authored or co-authored more than 170 articles in peer-reviewed medical/ scientific journals. He is either the first author or corresponding author in many of those papers. His interests and sub-specialities in the urological field include urological laparoscopic surgery, urological oncological surgery (especially prostate and kidney tumors), medical and surgical treatment of bladder outlet obstruction caused by prostate enlargement, primary aldosteronism and kidney transplantation.

Over the years he have developed several pioneer and innovative techniques in urological laparoscopy which were never reported before, including: Clipless Needlescopic Adrenalectomy [J Urol. 2002;16:39-42, Eur Urol. 2008;54:640-6], Clipless Pure Needlescopic Bilateral Varicocelectomy [J Androl. 2005;26:93-7], Clipless Needlescopic Partial Adrenalectomy [Urology. 2006;68:663-7.], A Novel Assisting Device for Simultaneous Bilateral Nephroureterectomy Without Changing Position of the Patient [J Urol. 2002;67:44-7.], A Modified Technique of Laparoscopic Nephropexy for Floating Kidneys [Surg Endosc. 2002;16:1603-7.], and A Modified Easier Access to Develop a Preperitoneal Working Space for Total Extraperitoneoscopic Herniorrhaphy and Extraperitonoscopic Radical Prostatectomy [Annals of Surgical Oncology 2008;15:2589-93.]. All these originalities and creativity have been attested by academic publications in highly-cited peer-reviewed journals. He is also a member of the Editorial Board for Transplantation Proceedings, Transplantation Reports, Asia Journal of Surgery, and World Journal of Clinical Urology; and a frequent invited reviewer for many urological and transplantation journals.

Rajeev Kumar

Rajeev Kumar


Dr Rajeev Kumar is Professor of Urology and Associate Dean for Academics at the All India Institute of Medical Sciences, New Delhi, India where he obtained all his medical training and graduated at the top of his class both for the basic and urology degrees.

His principal areas of clinical work are microsurgery, laparoscopy and robotics. His research interests focus on genetics of male infertility and magnetic resonance techniques for prostate cancer. He has published over 200 articles and book chapters. He has an interest in Journalology and conducts workshops, internationally, on medical writing and research methodologies.

He is Chief Editor of the Indian Journal of Urology and serves in various editorial capacities for the Journal of Urology, National Medical Journal of India, International Journal of Urology, Korean Journal of Urology Asian Journal of Urology, and the Journal of Men's Health. He is Secretary of the World Association of Medical Editors and serves as a co-opted executive committee member of the Urological Association of Asia by virtue of being chairman of its young urologists’ section and editor of its newsletter. He is a member of the National Academy of Medical Sciences of India.

Anthony Ng吳志輝

Anthony Ng

Anthony Ng


Outstanding Young Urologist Award 2010, Asian Congress of Urology, Taiwan 2010

Best Presentation on Prostate Disease, Asian Congress of Urology, Thailand 2012

Mae Joan Islami Scholar, International Guest Scholars, American College of Surgeons, 2012

Achievement award, the World Chinese Urology Association, 2014.

Dr NG Chi Fai, Anthony graduated in the Chinese university of Hong Kong in 1993. He then joined Department of Surgery, Prince of Wales Hospital, as surgical trainee. After his basic training, he decided to become an urologist and became a specialist in 2001. Attracted by the rapid development in endourology, he spent one year in Scotland, worked under Mr David Tolley, and gained extensive experience in endo-laparoscopic surgery and stone management.

After completion of his training, Dr Ng decided to join the Chinese University of Hong Kong in 2006 and is currently Director and Professor of the S.H. Ho Urology Centre, Department of Surgery, the Chinese University of Hong Kong. He is also the Course Director of the Robotic Surgery Training Programme, CUHK Hong Kong Jockey Club Minimally Invasive Surgical Skill Centre. He has a wide range of interest, in particular in prostate diseases, urolithiasis, and promotion of men’s health. He was also honored with the Outstanding Young Urologist Award in 2010 by the Asian Congress of Urology, the International Guest Scholar  2012 of the American College of Surgeons and the World Chinese Urology Association Award 2014, as recognitions to his work in the field.

Selvalingam Sothilingam

Selvalingam Sothilingam

Selvalingam Sothilingam


1) Awarded the title DIMP by his Royal Highness Sultan of Pahang which carries the title of Dato’ in May 2009.

2) Awarded the title of PAT (Pahlawan Angkatan Tentera) by his Royal Highness , the King of Malaysia in November 2010.

3) Sanofi-Syntelabo Best Prostate Research Prize at the Malaysian Urology Conference, 2010

4) Awarded Honorary Fellowship Royal College of Surgeons of Glasgow for distinction in Surgery, 2014.

Dr Selvalingam Sothilingam graduated from University of Malaya, Malaysia in 1992 and obtained Fellowship in General Surgery from the Royal College of Surgeons (Edinburgh) and MMed Surg (S’pore) in 1998. He went on to pursue Urology in 2002 and obtained Malaysian Board Certification in Urology in 2004.

He then spent a year and half in Melbourne, Australia doing a fellowship in Uro Oncology which included training in prostate brachytherapy from 2006-2007. His interest include Uro Oncology, Endourology and Robotic Assisted surgery and Reconstructive Urology.

Dr Selva also served in the Malaysian Armed Forces from 1993-2014 and left the service with a rank of Brigedear General. He also received an award from His Royal Highness King of Malaysia for his service in the military in 2010.

He has also been involved in community work and has been the founder of the Blue Cap Movement in championing Mens’ Health in Malaysia as well as co-founder of the Prostate Cancer Society Malaysia ( a society of prostate cancer survivors). Dr Selva initiated the Blue Cap Relay run for Prostate Cancer ,which is now an annual event in Kuala Lumpur. He has organized numerous nationwide prostate awareness campaigns in Malaysia.

He has been involved in research especially between 2014-2016 as a Consultant Urologist and Lecturer in University Malaya. He has published on Prostate Epidemiology in Malaysia and in 2015 initiated a large multicenter Stone study which is currently ongoing.

Dr Selva is now a consultant urologist in private practice and the current President of the Malaysian Urology Association.

Hendrik Van Poppel

Hendrik Van Poppel

Hendrik Van PoppelHendrik Van Poppel, MD, PhD is the Chairman of the Department of Urology at the University Hospital Gasthuisberg, Katholieke Universiteit (KU) Leuven, Belgium.

He graduated in General Surgery in 1980, in Urology in 1983 and joined the Academic Unit at KU Leuven after his postgraduate training in London, Barcelona, Copenhagen, Mainz and Rotterdam. In 1988, he obtained a PhD in Medical Sciences. He became a Fellow of the European Board of Urology (FEBU) in 1992, full Professor of Urology in 1993, and chair of the department of urology in Leuven in 2002. He was visiting Professor in Aachen (DE), Munster (DE), ‘s Hertogenbosch (NL), Linz (AU), Barcelona (SP), Jönköping (SE), Marburg (DE), Cardiff (UK), London (UK), Heidelberg (DE), Mainz (DE), Timisoara (RO) and Surabaya (ID) were he demonstrated live uro-oncologic surgery for kidney, bladder and prostate cancer. Other live demonstrations took place in Nijmegen (NL), Zaragoza (SP), L’Aquila (IT), Leuven (BE) and Brussels (BE).

He developed the original surgical technique for prepubic urethrectomy, percutaneous gastrostomy, lumbal splenectomy during orthotopic kidney transplantation, and of the Leuven “N”pouch for bladder substitution. He performed more than 2500 radical prostatectomies and actually only performs major open oncological surgery for kidney, bladder, prostate, testis and penile cancer.

He was co-founder and chairman of the European Study Group on Sexual and Urological Disorders in Multiple Sclerosis (SUDIMS) between 1991 and 1995, Treasurer of the EORTC Genito-Urinary Group between 1997 and 2011, Board Member of the EORTC between 2004 and 2008, President of the Belgian Association of Urology 2009 – 2010 and Treasurer of the International Consultation on Urological Diseases (ICUD) between 2009 and 2012.

During 8 years he was Director of the European School of Urology (ESU) and became EAU Adjunct Secretary General, responsible for Education, in 2012. He is a member of several international scientific organisations as the American Urological Association (AUA), the Société Internationale d’Urologie (SIU) and the American Association of Genito-Urinary Surgeons (AAGUS). He was Board Member of the European Society of Oncologic Urology (ESOU) and the European Society of Surgical Oncology (ESSO). He was co-founder and is now Chairman of the Scientific Committee of Europa Uomo, Faculty Member of the European Society of Medical Oncology (ESMO) and Board Member of ECCO on behalf of the EAU.

He is reviewer for 27 urological and uro-oncological journals. He is editorial Board Member of Uro-Oncology, Turkish Journal of Urology, Open Prostate Cancer Journal, Romanian Journal of Urology, European Urology, Annals of Urology, African Journal of Urology and Asian Journal of Urology.

He became honorary member of the Asociatia Romana de Urologie (ARU), the Dutch Urological Association (DUA), the Georgian Urological Association (GUA), the Hungarian Association of Urology (HSU), the Deutsche Gesellschaft für Urologie (DGU), the Chinese Urological Association (CUA) and the Polish Urological Association (PTU).

He received the Folke Edsmyr Award (for outstanding contribution to the progress of cancer research in Urology) in Stockholm in 1999 and the Pieter De Mulder Award (for his significant contribution in Urology for the treatment of renal cell carcinoma) in Lyon in 2015. He was promotor, co-promotor or jury member of more than 25 doctoral theses at the Katholieke Universiteit Leuven. He has published more than 200 papers as first author on uro-oncology and has co-authored more than 350 other ones and (co-) edited several books of kidney and prostate cancer.

His department in Leuven, is an EBU (European Board of Urology) accredited training centre, has obtained a subspecialty accreditation from EBU for Female Urology and Incontinence and for Oncologic Urology and hosts yearly about 30 visitors for short and intermediate stays and constantly 2 or 3 research fellows from all over the world, often in collaboration with the European Urology Scholarship Programme of the EAU (EUSP)

Prof. Dr. Hendrik Van Poppel

Department of Urology

University Hospitals Leuven Herestraat 49

Masato Fujisawa


Masato FujisawaDr. MASATO FUJISAWA

My specialty is endourology, especially robotic surgery, Urooncology, Andrology, Renal transplantation. I performed a clinical trial on robotic partial nephrectomy (RAPN) in 2014 and made a great contribution on the approvement of medical public insurance for RAPN in Japan.

Present Appointment

  1. President, Japanese Urological Association (2015~ Present)
  2. Vice President, Japanese Society of Endourology (2016~ Present)
  3. Director, Kobe University Hospital (2014~ Present)

Career Highlight:

  1. Professor and Chairman, Department of Urology, Kawasaki Medical School (2002-2005)
  2. Professor and Chairman, Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine (2005~ Present)

Academic Background (please indicate period):

  1. Graduated from Kobe University School of Medicine (1984)
  2. PhD, Kobe University Graduate School of Medicine (1989)

Honor and Awards:

Maenosono Award

Professional Affiliation / Membership:

  1. Japanese Urological Association
  2. American Urological Association
  3. SIU

Publications Highlights:

  1. Current status of robotic partial nephrectomy in Japan.
    Hinata N, Fujisawa M.
    Investig Clin Urol. 2016 Dec;57(Suppl 2):S121-S129. Review
  2. Renal Functional and Perioperative Outcomes of Selective Versus Complete Renal Arterial Clamping During Robot-Assisted Partial Nephrectomy: Early Single-Center Experience With 39 Cases.
    Furukawa J, Miyake H, Hinata N, Muramaki M, Tanaka K, Fujisawa M.
    Surg Innov. 2016 Jun;23(3):242-8.
  3. Impact of Periurethral Inflammation on Continence Status Early After Robot-Assisted Radical Prostatectomy.
    Momozono H, Miyake H, Fujisawa M.
    J Endourol. 2016 Nov;30(11):1207-1213


Peter Heathcote

Peter S Heathcote

Peter HeathcoteA/Prof Peter S Heathcote

Peter is a Urologic Surgeon with a special interest in Cancer of the Prostate and Robotic Surgery and Pelvic Oncology and is Senior Urologist at the Princess Alexandra Hospital and Chairman of Robotic Surgery at Greenslopes Private Hospital where the first Robotic Prostatectomy in Queensland was performed. Having completed Urology Speciality training in Queensland Peter spent further time in Cardiff, United Kingdom and in Toronto, Canada developing Radical Prostatectomy skills.


Adjunct Professor - Australian Prostate Cancer Research Centre- Queensland

Senior Examiner in Urology Royal Australasian College of Surgeons

President Urological Society of Australia and New Zealand 2017- 19.

Senior Lecturer in Medicine University of Queensland


HEATHCOTE,P.S. ,MACTAGGART,P.,BOSTON,R.,J. et al. Health-related quality of life in Australian men remaining disease-free after Radical Prostatectomy. Med J Aust (1998); 168: 483-486.

STEGINGA, S. OCCHIPINTI, S. GARDINER, R. YAXLEY, J. HEATHCOTE, P.S. “Making Decisions About Treatment for Localised Prostate Cancer”. British Journal of Urology (2002) Vol.89:255-260

Rhee H, Gunter J, Heathcote P, Ho K, Stricker P, Corcoran N, et al. Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and Their Management. BJU international. 2014; 115, S5, 3-13.

Rhee H, Paterdis J, Heathcote P. Robot-assisted laparoscopic radical prostatectomy using modular training programme in a private hospital. J Robotic Surg. 2013;7(4):339-44.

M TRAN, P DALY, T TRAN, P HEATHCOTE. Renal Cell Carcinoma metastases to the spermatic cord: review of the literature and case presentation. Jnl of Clinical Urology (6) 6 Nov 13 427-431


Heathcote P, Kanagarajah A. Multidisciplinary Team Approach to Interpreting PSMA PET Data in Men with Prostate Cancer. ANZUP, Brisbane. Asia-Pacific Journal of Clinical Oncology, 2016, 12 (3).

Heathcote P, Patel A, Rhee H. Outcomes of Salvage Lymph Node Dissection for Oligometastatic Recurrent Prostate Cancer after Radical Prostatectomy: Results of a Single-Institution Multidisciplinary Team Series. ANZUP, Brisbane. Asia-Pacific Journal of Clinical Oncology, 2016, 12 (3).

Heathcote P, Nicholson C, Rhee H et al. Histopathological correlation of lesions identified by hybrid PET/MRI using novel 68 Ga PSMA inhibitor. USANZ, Gold Coast, 2016.

Heathcote P, Kanagaraja A, Rhee H et al. Multi-Disciplinary team initiated 68 Ga PSMA PET/CT can be used to change patient treatment outcomes. USANZ, Gold Coast, 2016.

Heathcote P, Rhee H et al. PSMA PET improves diagnostic accuracy of mpMRI in localized prostate cancer as confirmed by whole mount histopathology: implications for selection and assessment for active surveillance and focal therapy. EAU, Munich, 2016.

Jun Cheon

Jun Cheon

Jun Cheon

Guo-Hua Zeng曾國華




中山醫科大學博士畢業,師從我國著名泌尿外科專家梅驊教授。2006年2月上海交通大學博士後,2007年美國德克薩斯大學西南醫學中心訪問學者。曾先後在南華大學(原衡陽醫學院)附屬第一醫院、湖南醫科大學湘雅醫院、中山醫科大學第一附屬醫院、上海市第一人民醫院、等醫學院校及醫院學習和工作。專業理論豐富、知識面廣,臨床基本功扎實,經驗豐富,能得心應手地處理本專業常見病和一些疑難複雜病例,如腎上腺腫瘤、腎癌根治術、膀胱癌根治術與原 位新膀胱,兒童尿道下裂膀胱黏膜一期尿道成型術等。近年來,致力於微創技術治療泌尿系疾病,尤其是微創經皮腎穿刺技術治療腎結石、輸尿管鏡技術治療輸尿管結石、輸尿管狹窄、開放手術後UPJO

  • 專家中國醫師協會內鏡醫師分會常務委員
  • 廣東中西醫結合學會泌尿外科委員會副主任委員
  • 廣東省抗癌協會泌尿生殖專業委員會副主任委員
  • 廣東省醫師協會泌尿外科分會副主任委員
  • 廣東省醫學會泌尿外科學分會常務委員
  • 廣東省醫學會微創外科學分會委員兼泌尿學組組長
  • 廣州市醫學會男科學分會副主任委員
  • 廣州市醫學會泌尿外科學分會副主任委員
  • 衛生部內鏡專業技術培訓基地主任
  • 衛生部內鏡專業技術考評委員會泌尿外科內鏡專業技術考評
  • 衛生部內鏡專業技術考評委員會泌尿專科內鏡專家委員會副主席
  • 《中國內鏡雜誌》副主編;
  • 《中華泌尿外科雜誌》編委
  • 《中華腔鏡泌尿外科雜誌(電子版)》常務編委
  1. 2006年:獲中華醫學科技獎二等獎
  2. 2007年:獲廣東省科技進步二等獎
  3. 2008年:獲教育部科技進步二等獎; “恩德思醫學科學技術獎”一等獎;第五屆“恩德思醫學科學技術獎”傑出成就獎
  4. 2009年:“恩德思醫學科學技術獎”中國內鏡傑出領袖獎
  5. 2010年:“恩德思醫學科學技術獎”國際內鏡傑出領袖獎
  6. 2010年:中華醫學會泌尿外科分會鑽石獎;2010年國家科技進步二等獎


Bin Tean Teh鄭敏展

Bin Tean Teh

Bin Tean Teh鄭敏展

Dr Teh obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden. Following postdoctoral works at Karolinska Institute, he joined the Van Andel Research Institute (VARI), USA in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. From 2003, he served as the Deputy Director (Research Operations) of VARI and from 2008, Director of VARI International. He established the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the Singapore Translational Research Investigator Award and relocated to Singapore. He served as the SingHealth Group Director for Translational Research from 2010-2012. His laboratory focuses on Asian Cancer Genomics and in the last 5 years have made seminal discoveries in the field including biliary tract cancer, urological cancer and breast tumors. He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden. Dr. Teh has published extensively, with over 350 publications in high impact scientific journals. He is a past and present member of numerous editorial boards for journals including Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics. Dr Teh is a recipient of the 2015 Singhealth Distinguished Researcher Award and co-recipient of the 2015 Singapore President Science Award.


Epigenomes (from 2014)

Molecular Cancer Therapeutics (from 2013)

Urological Science (from April 2012)

Endocrine-Related Cancer Editorial Board (from 2012-2017)

Frontiers in Urogenital Cancer (from Sept 2011)

Advances in Molecular Imaging (AMI) (from Jan 2011)

Clinical Genitourinary Cancer (from 2010)

The Lancet Oncology International Advisory Board (from 2010)

Cancer Research, Associate Editor (from 2006)

Journal of Clinical Endocrinology and Metabolism (2008 - 2012)

American Journal of Translational Research (from 2008)

Open Cancer Journal (from 2007)

Singapore Medical Journal (from 2000–2005)

Current Cancer Therapy Reviews (from 2004)

Asia Pacific Journal of Molecular Biology and Biotechnology (2003)

Journal of Endocrine Genetics (from 2003)

International Journal of Oncology (from 2002)

Clinical Genitourinary Cancer (from 2014)

Osamu Yokoyama

Osamu Yokoyama

Osamu Yokoyama

Osamu Yokoyama is a Professor & Chairman, Department of Urology, University of Fukui and Director of the Kidney Center in the University Hospital of Fukui, Fukui, Japan. He undertook his medical training at the Kanazawa University Hospital and was awarded the degree of PhD in Neurourology for a thesis entitled "Nerve degeneration in ischemic dog urinary bladders". He worked as a Visiting Assistant professor at Department of Pharmacology, School of Medicine, Pittsburgh University under the direction of Professor William C. de Groat from 1996 to 1997. He is active in basic and clinical researches with many major grants-in-Aid for Scientific Research funding from Japanese Government and has published over 130 research papers and reviews including 30 original articles published in Journal of Urology. He is now a President of the Japanese Continence Society and a Steering Committee Member of Pan-Pacific Continence Society

Seung-June Oh

Seung-June Oh

Seung-June Oh

Dr. Seung-June Oh is currently Professor of Urology at the Seoul National University College of Medicine.

After completing his undergraduate and graduate training at Seoul National University, Professor Oh pursued fellowship at the Seoul National University Hospital, Asan Medical Center, and the University of Michigan, Ann Arbor in the U.S under the supervision of Professor Edward J. McGuire. He is specializing in neurourology and reconstructive surgery.

In recent years, Professor Oh has authored or co-authored over 214 peer reviewed papers and contributed to 14 book chapters, including a chapter in the 9th edition of Campbell’s Urology textbook as the first author. His primary interest is in benign prostatic hyperplasia (BPH) and neuropathic lower urinary tract dysfunction. He has performed over 1200 cased of Holmium Laser Enucleation of Prostate or HoLEP for BPH since 2008. Outside his medical specialty, he is in medical device-related positions: he is the Director of the Medical Device Innovation Center of the Seoul National University Hospital. Professor Oh is currently serving as the President of the Korean Continence Society starting Jan. 2016 and the President of Pan-Pacific Continence Society since October 2016.

Kexin Xu許克新

Kexin Xu

Kexin Xu許克新

Dr. Xu has focused his clinical and research interests on the functional urology, bladder cancer and prostate cancer.

Professional Highlights:

He is the past vice-president of the Youth Committee of the Chinese Urological Association,the vice-president of CUA Continence Society, and the vice-chair of international communication committee of CUA. He is also an Editorial Board Member of Chinese Journal of Urology, Chinese Overactive Bladder Guideline. He has obtained national grants and several other grants.


He has authored over 60 scientific papers published in peer-reviewed international and local journals.

Won Hee Park

Won Hee Park

Won Hee Park

Professor, Urology, Inha University Hospital College of Medicine, Inha University, Incheon, Korea M.D., Seoul National University (Medicine), 1979 Ph.D., Seoul National University (Medicine), 1989

Urologic training in Seoul National University Hospital, 1980-1983 Staff, Department of Urology, Korean Veterans Hospital, 1986-1995 Associate professor, College of Medicine, Inha University, 1995-2000 Professor, College of Medicine, Inha University, 2000~present Head, Department of Urology, Inha University Hospital, 2004 ~ 2008 Professor in charge, Department of Urology, College of medicine, Inha University, 2002~2008

Korean Continence Society, founding member, president, 2000-2003 Korean Urological Association, director 2005-2012 Incheon-Gyonggido Branch, Korean Urological Association, chairman, 2011-2012 Korean Continence Society, director 2003-2015 Korean Spinal Cord Society, president, 2014-2015 Healthcare Review and Assessment Committee, member, 2016 - present

Pan-Pacific Continence Society, founding member; committee member, 2006 - 2016 Associate editor, LUTS Reviewer in Journal of Korean Urology, International Journal of Urology, Journal of Korean Medical Science, Neurourology and Urodynamics, Adis Drug Evaluation (in-house written) articles, Indian Journal of Urology, Journal of Clinical Medicine and Research (JCMR)

Nicolas Mottet

Nicolas Mottet

Nicolas Mottet

Professor Nicolas Mottet, MD, PhD is Head of the Urology Department, University Hospital, and Professor of Urology, University Jean Monnet, Saint-Etienne, France. He is board certified in surgery, urology and medical oncology. He is chairman of the EAU Working Group on Prostate Cancer Guidelines, board member of the Urology Group for the French Anti-Cancer Centre Federation, and member of the SIOG prostate and bladder cancer guidelines. He is the former coordinator the Testis and Penile Cancer Subgroup (French Urological Association 2000 – 2008). He has published over 160 peer-reviewed papers and made numerous presentations and lectures; he is member of the Editorial Board of the European Urology Journal and a reviewer of more than a dozen of high profile journals including the New England Journal of Medicine. He sits on the scientific advisory board of several multinational pharmaceutical companies. He coordinated or participated to more than 40 clinical trials and received several national grants. He is member of the AUA, AFU, ASCO, EAU, ESMO and SIOG.

Timothy G Wilson

Timothy G Wilson

Timothy G Wilson


American Board of Urology, Board Certification # 10377

Part I, passed June 1990.

Part II, passed Feb. 1992.

Recertification passed Nov 2000.

Recertification passed Nov. 2012.

Dr. Timothy Wilson graduated from Stanford University and received his medical degree at Oregon Health Science University. He completed general surgery and urology training at the University of Southern California, and performed a fellowship in urologic oncology at City of Hope Cancer Center. Dr. Wilson was Chief of Urology/Urologic Oncology at City of Hope from 1992 through 2015. Currently, he is Professor and Chair of Urology and the Director of Urologic Oncology Research at the John Wayne Cancer Institute at Providence Saint John’s Health Center.

Dr. Wilson was a pioneer in performing laparoscopic prostatectomy and laparoscopic radical cystectomy, and a leader in the use of minimally invasive techniques for urinary reconstruction, robot assisted retroperitoneal and pelvic lymphadenectomy, robotic radical cystectomy for pelvic cancer and robot assisted radical prostatectomy.

His goal, “Deliver the best possible cure with the least side effects”.

Mototsugu Oya

Mototsugu Oya

Mototsugu Oya

Dr Mototsugu Oya obtained his medical degree (1987) and his Ph.D. (1994) from the Keio University School of Medicine, Japan. Dr Oya studied at the Department of Urology, New York Medical College, USA (1995-1996), and Department of Urology, Dusseldorf University, Germany (1997-1998). He is currently the Professor and Chairman, Department of Urology, Keio University School of Medicine and also holds Vice Director, Keio University Hospital. Additionally, Dr Oya has published extensively over 294 publications in high impact scientific journals. He joins in various Editorial Boards such as International Journal of Urology, Cancer Science, International Case Conference Journal, Clinical and Experimental Nephrology, World Journal of Urology, International Journal Clinical Oncology, and the Japanese Journal of Clinical Oncology. He is an emeritus editor-in-chief of International Journal of Urology. He was awarded the Japan Urology Association Award (2005). He recently published the book titled Renal Cell Carcinoma-Molecular Features and Treatment Updates-, Springer (2017).

Oliver Sartor

Oliver Sartor

OliverOliver Sartor, MD


Dr. Oliver Sartor is the only medical oncologist in Louisiana specializing in the treatment of prostate cancer patients. Dr. Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of Tulane School of Medicine, helps to complete the world-class prostate cancer team at the Tulane Cancer Center. Together, Lee, Sartor and Thomas are overseeing the prostate cancer program that offers state-of-the-art clinical and surgical care. Before joining Tulane’s faculty, Sartor was an associate professor in the Lank Genitourinary Oncology Center at Harvard’s Dana-Farber Cancer Institute in Boston. He is also chair-elect of the Department of Defense Prostate Cancer Integration Panel, which directs over $70 million in federal funding for prostate cancer research.

Sartor was previously at the Louisiana State University Health Sciences Center in New Orleans, where he was the director of the Stanley S. Scott Cancer Center. He was also co-director of the Louisiana Cancer Research Consortium, a legislatively established tobacco tax funded public-private partnership focused on enhancing cancer research in Louisiana.

Sartor has a clinical and scientific interest in advanced prostate cancer. Specifically, his research has focused on novel therapies for prostate cancer.

Prior to his return to New Orleans, Dr. Sartor was an associate professor of medicine at Harvard Medical School.

Sartor is the editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer and the author of more than 100 scientific papers. He received his medical degree from Tulane University, and completed a fellowship with the National Cancer Institute. He is a member of several professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Urological Association, and the Society of Urologic Oncology, and board certified in internal medicine and medical oncology.

Darren Poon潘明駿

Darren Poon

Darren PoonPoon Ming Chun Darren


Dr. Darren Poon is a clinical oncologist and serves as the consultant in the Department of Clinical Oncology at Prince of Wales Hospital (PWH) in Hong Kong. He is also the honorary clinical assistant professor at the Chinese University of Hong Kong. Dr. Poon graduated in the Chinese University of Hong Kong and had undergone training in the MD Anderson cancer center and Medical College of Wisconsin after obtaining the FRCR.

He specializes in the genitourinary cancer, neuro-oncology, hepato-pancreatic cancer and head and neck cancer. His research interests include image-guided radiotherapy (IGRT) and stereotactic body radiotherapy (SBRT) for prostate, CNS tumour, pancreatic and liver cancer. He is currently the supervisor of the stereotactic radiosurgery and SBRT for prostate, CNS and hepato-pancreatic cancer service in PWH. He dedicated himself in building-up the patient-centered and multidisciplinary (MDT) care for patients with genitourinary (GU) cancer at new-territories east cluster (NTEC) of Hospital Authority and he is the key driver for the successful MDT GU cancer service in both PWH and North district hospital (NDH).

Dr. Poon actively participated in clinical research. In 2010, he was awarded the Best Proffered Paper Presentation at the 18thannual scientific meeting of the Hong Kong College of Radiologists. Dr. Poon is currently the member of the scientific subcommittee of the Hong Kong College of Radiologists. And he is the convener and the current vice-president of Hong Kong Society of Uro-Oncology (HKSUO). Dr. Poon is also the honorary secretary of the Hong Kong Nasopharyngeal cancer (NPC) study group. He had published actively in various peer-reviewed journals. He is an invited reviewer of various journals including International Journal of Radiation Oncology Biology Physics, Asian-Pacific Journal of Clinical Oncology, Hong Kong Medical Journal and Hong Kong Journal of Radiology.

He also enthusiastically contributed himself in community charity services and he is now the vice-chairman of Hand in Hand Cancer foundation and the council member of Hong Kong Prostate Foundation.


  • 2012: Fellow of the Hong Kong Academy of Medicine (FHKAM (Radiology))
  • 2012: Fellow of the Hong Kong College of Radiologists (FHKCR)
  • 2009: Fellow of the Royal College of Radiologists (FRCR)
  • 2002: Bachelor of Medicine and Surgery (MBChB). The Chinese University of Hong Kong




  • Genitourinary Cancer
  • Neuro-oncology
  • Head and Neck Cancer
  • Hepato-pancreatic cancer

Position Held

  • Resident at Department of Clinical Oncology, PWH (July 2003 – Dec 2011)
  • Resident specialist at Department of Clinical Oncology, PWH (Jan 2012 – Oct 2013)
  • Associate consultant at Department of Clinical Oncology, PWH (Nov 2013 – Jan 2017)
  • Consultant at Department of Clinical Oncology, PWH (Feb 2017 – now)
  • Honorary clinical assistant professor, CUHK (Nov 2013 – now)
  • Member, QA subcommittee, Central Coordinating Committee in Clinical Oncology, Hospital Authority (Jan 2017–now)
  • Secretary, The Hong Kong Nasopharyngeal carcinoma study group (Oct 2015 – now)
  • Vice-President, The Hong Kong Society of Uro-Oncology (Jul 2015 – now)
  • Council member, The Hong Kong Prostate Foundation (Jul 2016 – now)
  • Vice-chairman, The Hand in Hand Cancer Foundation (Jul 2016–now)


The best proffered paper presentation in 18th annual scientific meeting of Hong Kong College of Radiologists, 2010 (Intensity modulated radiotherapy for prostate cancer: toxicity and biochemical control in 183 Chinese patients form Single institutions in Hong Kong)

Education & Training


  • Honorary clinical assistant professor, CUHK (Nov 2013 – now)
  • Teaching in HKCR/FRCR part II training course, HKCR/HKCR (2009 – now)
  • Teaching in urology trainee training course, Hong Kong Urology Association (2009 – now)
  • Coordinator of radiation therapist’s contouring workshop, PWH (2016 – now)

Administrative experience and qualification

  • Management program 101 for new leaders, HA (2015)
  • Secretary for Clinical Oncology team, PWH (2009 – 2011)
  • Members, working group for Linear accelerator replacement, PWH (2016 – now)
  • Editor, management guideline for prostate cancer, head and neck cancer, GBM, PWH (2009 – now)


  • Darren MC Poon et al. The efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. Hong Kong Med J. 2013 Jun 20
  • Darren MC Poon et al. Dosimetric Advantages And Superior Treatment Delivery Efficiency Of RapidArc Over Conventional Intensity-modulated Radiation Therapy In Radiation Therapy Planning For High Risk Prostate Cancer Involving Seminal Vesicles And Pelvic Nodes. Clin Oncol. 2013 Aug 15 (presented at ASTRO annual meeting 2011, Miami, USA)
  • Darren MC Poon et al. Abiraterone acetate in metastatic castration-resistant prostate cancer the unanticipated real-world clinical experience. BMC Urol. 2016 Mar
  • Darren MC Poon, Ng J, Chan K. The importance of cycles of chemotherapy and post-docetaxel novel therapies in metastatic castration-resistant prostate cancer (mCRPC). Prostate Int. Feb 2015
  • Darren MC Poon et al. The impact of image-guided radiotherapy (IGRT) for prostate cancer (PC) on radiotherapy (RT)-related acute toxicities and prostate-specific antigen (PSA) kinetics. J Clin Oncol 30, 2012 suppl; abstr e15110 (Presented as abstract at ASCO annual meeting 2012, Chicago, USA)
  • Darren MC Poon et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer: Toxicity and biochemical control in 183 Chinese patients from a single institution in Hong Kong. J Clin Oncol 29: 2011 (suppl 7; abstr 101) (Presented at ASCO GU cancer symposium 2011, Orlando, USA)
  • Darren MC Poon et al. Application of abiraterone acetate (AA) in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients who did not fulfil the patient inclusion criteria in the COU-AA-302 study. J Clin Oncol 34, 2016 suppl 2S; abstr 317 (Presented as abstract at ASCO GU cancer symposium 2016, San Francisco, USA)
  • Teoh JY, Chiu PK, Chan SY, Poon DM et al. Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male 2015 May
  • Teoh JY, Chiu PK, Chan SY, Poon DM et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl. 2014 Dec
  • Teoh JY, Chiu PK, Chan SY, Poon DM et al. Risk of New-onset Diabetes after Androgen Deprivation Therapy for Prostate Cancer in the Asian Population. J Diabetes. 2014 Sep
  • Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of Acute Myocardial Infarction after Androgen Deprivation Therapy for Prostate Cancer in the Chinese Population. BJU Int 2014 Oct
  • Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl 2014 Dec
  • Teoh JY, Chan SY, Chiu PK, Poon DM et al. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol. 2015 Feb
  • Stephen L Chan, Frankie Mo, Philip Johnson, Giok S Liem, Tung C Chan, Ming C Poon et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for HCC in Asian populations. Journal of Gastroenterology and Hepatology 2011
  • Chan SL , Mo FK , Wong VW , Liem GS , Wong GL , Chan VT , Poon DM , Loong HH , Yeo W , Chan AT , Mok TS , Chan HL . Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int 2012
  • Chan SL, Johnson PJ, Mo F, Berhane S, Teng M, Chan AW, Poon MC et al. International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014 Oct
  • Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol. 2016 Aug
  • Danny TM Chan, Sonia YP Hsieh, Claire KY Lau, Michael KM Kam, Herbert HF Loong, WK Tsang, Darren MC Poon, WS Poon. Ten-year review of survival and management of malignant glioma in Hong Kong. HKMJ Dec 2016
  • Darren MC Poon et al. Palliative Radiotherapy for Patients with Locally-advanced or Metastatic Bladder Cancer. (Presented at Palliative care symposium for health care workers in Chinese population 2011)

Zhi-Hui Xn 徐智慧

Zhi-Hui Xn

Zhi-Hui Xn